10-Q: OSI Systems Q2 FY26: Revenue Growth & Strategic Refinancing

OSI Systems reports strong Q2 fiscal 2026 revenue growth driven by its Security division, alongside significant debt refinancing and share repurchases.

Summary

• Total net revenues for the three months ended December 31, 2025, increased by 10.5% to $464.0 million, up from $419.9 million in the prior year period.
• Total net revenues for the six months ended December 31, 2025, increased by 11.1% to $848.7 million, up from $763.8 million in the prior year period.
• Net income for the three months ended December 31, 2025, was $38.7 million, compared to $37.8 million in the prior year period.
• Diluted earnings per share for the three months ended December 31, 2025, remained flat at $2.22, compared to $2.22 in the prior year period.
• Net income for the six months ended December 31, 2025, was $59.3 million, compared to $55.8 million in the prior year period.
• Diluted earnings per share for the six months ended December 31, 2025, increased to $3.39, up from $3.27 in the prior year period.
• The Security division's revenue increased by 15.4% for the quarter and 14.5% for the six months, driven by aviation screening systems, RF products, and service revenue.
• The Optoelectronics and Manufacturing division's revenue increased by 9.2% for the quarter and 8.8% for the six months, primarily due to growth in contract manufacturing.
• The Healthcare division's revenue decreased by 18.7% for the quarter and 5.6% for the six months, mainly due to lower patient monitoring sales.
• Gross profit increased by $4.5 million for the quarter and $6.1 million for the six months, but gross margin decreased due to a less favorable product mix in the Security division.
• Impairment, restructuring, and other charges significantly increased to $2.9 million for the quarter (from $0.2 million) and $5.6 million for the six months (from $1.4 million).
• Interest and other expense, net, increased due to a $4.4 million charge for prior service cost amortization related to a pension plan amendment for a former CEO in December 2025.
• Cash and cash equivalents increased to $336.7 million at December 31, 2025, from $106.4 million at June 30, 2025.
• Issued $575.0 million principal amount of 0.50% convertible senior notes due February 2031 in November 2025.
• Repurchased 546,945 shares of common stock for $146.1 million in connection with the 2031 Notes issuance.
• Amended and extended the revolving credit facility in July 2025, increasing the limit to $725 million and replacing a $128.1 million term loan with a new $100.0 million term loan.
• One condition for conversion of the 2.25% convertible senior notes due 2029 was met as of December 31, 2025, allowing holders to convert from January 2, 2026, through March 31, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, driven by strong revenue growth in key segments and improved liquidity, despite some margin compression and increased restructuring charges. The strategic debt issuance and credit facility amendment strengthen the company's financial position.

Positives

• Consolidated net revenues increased by 10.5% for the three months and 11.1% for the six months ended December 31, 2025.
• Net income and diluted EPS showed growth for both the three and six-month periods.
• The Security division demonstrated strong revenue growth of 15.4% for the quarter and 14.5% for the six months.
• The Optoelectronics and Manufacturing division also grew revenues by 9.2% for the quarter and 8.8% for the six months.
• Cash and cash equivalents significantly increased to $336.7 million at December 31, 2025, from $106.4 million at June 30, 2025.
• Net cash provided by operating activities for the six months ended December 31, 2025, was $79.3 million, a substantial increase from $15.4 million in the prior year period.
• Successfully issued $575.0 million in 0.50% convertible senior notes due 2031, enhancing liquidity.
• Amended and extended the revolving credit facility, increasing the limit to $725 million and extending its maturity to July 2030.
• Selling, general and administrative expenses were comparable year-over-year for the quarter despite an 11% increase in revenues, indicating improved operational leverage.
• The effective tax rate decreased to 19.5% for the quarter and 19.7% for the six months ended December 31, 2025.

Negatives

• The Healthcare division's revenue decreased by 18.7% for the quarter and 5.6% for the six months, primarily due to lower patient monitoring sales.
• Gross margin decreased from 35.0% to 32.7% for the quarter and from 35.2% to 32.4% for the six months, attributed to a less favorable product mix in the Security division.
• Impairment, restructuring, and other charges increased significantly by 1,350% for the quarter and 300% for the six months.
• Interest and other expense, net, increased due to a $4.4 million charge for prior service cost amortization related to a pension plan amendment for a former CEO.
• Repurchased common stock for $146.1 million, utilizing a significant amount of cash.
• One customer in the Security division accounted for 41% of accounts receivable, net, at December 31, 2025, indicating customer concentration.

Risks

• Exposure to global macroeconomic factors, including supply chain environment, inflationary pressure, interest rates, and labor shortages.
• Uncertainty due to increasing diplomatic and trade friction between the U.S. and China.
• Impact of political unrest internationally and the volatile U.S. political climate on demand for products and services.
• Potential for broad economic disruption and increased cyber-activity due to the continued conflict between Russia and Ukraine.
• Changes in domestic and foreign government spending, budgetary, procurement, and trade policies adverse to business.
• Material delays and cancellations of orders or deliveries, supply chain disruptions, or plant closures.
• Unfavorable currency exchange rate fluctuations, particularly a strengthening U.S. dollar.
• Unfavorable interest rate fluctuations.
• Impact of potential information technology, cybersecurity, or data security breaches.
• Market acceptance of new and existing technologies, products, and services.
• Ability to win new business and convert orders received to sales within the fiscal year.
• Contract and regulatory compliance matters, which could result in judgments, settlements, fines, injunctions, debarment, or penalties.
• Hospitals facing significant financial pressure, potentially adversely impacting capital equipment spending in the Healthcare division.
• Repatriation tax considerations for approximately 32% of cash held by foreign subsidiaries.
• Customer concentration risk, with one customer in the Security division accounting for 41% of accounts receivable, net.
• Unfavorable outcomes in legal proceedings could have a material adverse effect on business, financial condition, results of operations, or cash flows.
• Environmental contingencies, if resolved adversely, could have a material impact on business, financial condition, results of operations, and cash flow.

Future Outlook

The company anticipates that its available funds, credit facilities, and cash flow from operations will be sufficient to meet operational cash needs for the next 12 months and the foreseeable future. It also expects cash generated from operations, without repatriating earnings from non-U.S. subsidiaries, and credit facilities to satisfy current obligations in the U.S. The financial impact of the recently signed One Big Beautiful Bill Act (OBBBA) is currently being evaluated for the fiscal year ending June 30, 2026, which may affect the timing and recognition of certain deductions, the effective tax rate, and deferred tax balances in future periods.

Management Comments

• "We currently anticipate that our available funds, credit facilities and cash flow from operations will be sufficient to meet our operational cash needs for the next 12 months and the foreseeable future beyond that."
• "We anticipate that cash generated from operations, without repatriating earnings from our non-U.S. subsidiaries, and our credit facilities will be sufficient to satisfy our current obligations in the U.S."
• "We intend to permanently reinvest certain earnings from foreign operations, and we currently do not anticipate that we will need this cash in foreign countries to fund our U.S. operations."

Industry Context

StockSavvy.ai notes that OSI Systems' strong performance in its Security division aligns with increasing global demand for advanced security screening solutions, driven by geopolitical tensions and evolving threat landscapes. The decline in the Healthcare division, particularly in patient monitoring sales, reflects broader industry challenges faced by hospitals, including supply chain constraints, inflationary pressures, and capital equipment spending reductions, as mentioned in the filing. The company's strategic acquisitions in military, space, and surveillance solutions indicate a move to diversify and strengthen its defense and aerospace market presence within the Security division.

Comparison to Industry Standards

• The filing does not provide specific comparisons to industry benchmarks or named competitors.
• StockSavvy.ai's analysis suggests the decline in the Healthcare division's patient monitoring sales could be compared to the performance of major medical device companies like Medtronic, Philips, or GE HealthCare in their patient monitoring segments, which have also faced supply chain and hospital budget pressures.
• The growth in the Security division, particularly in aviation screening, could be benchmarked against peers such as Leidos, L3Harris Technologies, or Smiths Detection, who operate in similar security and defense markets.

Legal Proceedings

• Involved in potential or actual claims, litigation, and other legal proceedings arising in the ordinary course of business.
• Management believes the ultimate disposition of such proceedings is not likely to have a material adverse effect on business, financial condition, results of operations, or cash flows.
• No liability has been accrued for non-ordinary course matters as they are not considered probable and reasonably estimable.

Stakeholder Impact

• Shareholders: Positive impact from increased net income and EPS, and share repurchases. Potential dilution from convertible notes if conversion price is met.
• Employees: Impacted by employee terminations as part of restructuring charges ($0.7 million in Q2 FY26, $1.1 million in YTD Q2 FY26).
• Customers: Security division customers benefit from increased product and service offerings. Healthcare customers may face continued financial pressures impacting their purchasing decisions.
• Creditors: Strengthened financial position through new convertible notes and extended credit facility.

Next Steps

• Holders of the 2029 Notes have the right to convert their notes from January 2, 2026, through March 31, 2026.
• The company is evaluating the financial impact of the One Big Beautiful Bill Act (OBBBA) for the fiscal year ending June 30, 2026.
• The first interest payment for the 2031 Notes is due on August 1, 2026.
• Unrecognized compensation cost for stock options and RSUs is expected to be recognized over weighted average periods of 2.3 years.
• There are 643,611 shares remaining available for repurchase under the authorized stock repurchase program.

Key Dates

Recommendation

While OSI Systems demonstrated solid revenue growth and improved operating cash flow, the decline in gross margin and the Healthcare division's performance, coupled with significant restructuring charges and a one-time pension expense, present a mixed picture. The successful debt refinancing and share repurchases are positive for capital structure, but the overall growth trajectory needs to be balanced against these headwinds and the broader macroeconomic uncertainties. A "hold" recommendation reflects the company's resilience in core segments but acknowledges areas requiring close monitoring for sustained improvement.

Keywords

Security systems, optoelectronics, healthcare, patient monitoring, defense, aerospace, manufacturing, convertible notes, stock repurchase, supply chain, cybersecurity, global trade, tariffs, R&D, SEC filing, 10-Q